Literature DB >> 18445344

Activity after site-directed mutagenesis of CD59 on complement-mediated cytolysis.

Xinhong Zhu1, Meihua Gao, Shurong Ren, Qiubo Wang, Cunzhi Lin.   

Abstract

CD59 may inhibit the cytolytic activity of complement by binding to C8/C9 and protect host cell membranes against homologous membrane attack complex (MAC). However, CD59 is widely overexpressed on tumor cells, which has been implicated in tumorigenesis. The active site of CD59 relative to MAC is still confused. As reported the MAC binding site is located in the vicinity of a hydrophobic groove on the membrane distal face of the protein centered around residue W40. Here two site-directed mutagenesis were performed by overlapping extension PCR to delete residue W40 site (Mutant 1, M1) or to change C39W40K41 to W39W40W41 (Mutant 2, M2). Then we constructed mutant CD59 eukaryotic expression system and investigated their biological function on CHO cells compared with wild-type CD59. Stable populations of CHO cells expressing recombinant proteins were screened by immunotechnique. After 30 passages culturing, proteins could be tested. Dye release assays suggest that M1CD59 loses the activity against complement, while M2CD59 increases the anti-complement activity slightly. Results indicate that W40 of human CD59 is important to its activity, and prohibition of this site may be a potential way to increase complement activity and to treat tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18445344      PMCID: PMC4651242          DOI: 10.1038/cmi.2008.17

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  1 in total

1.  Overexpression of CD59 inhibits apoptosis of T-acute lymphoblastic leukemia via AKT/Notch1 signaling pathway.

Authors:  Yanfei Jia; Yan Qi; Yunshan Wang; Xiaoli Ma; Yihui Xu; Jun Wang; Xiaoqian Zhang; Meihua Gao; Beibei Cong; Shuyi Han
Journal:  Cancer Cell Int       Date:  2019-01-08       Impact factor: 5.722

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.